Factors Influencing Adverse Events Following Immunization (AEFI) of the COVID-19 vaccine: A Case Study in Ubon Ratchathani Province, Thailand

ABSTRACT

Background: The rapid development, approval, and distribution of these vaccines highlight the need to carefully assess their safety. One significant concern is the incidence of Adverse Events Following Immunization (AEFI). There are few reports on the factors influencing AEFI and differences in AEFI among different COVID-19 vaccine brands in Thailand. Exploration of the incidence and factors related to post-vaccination adverse reactions against SARS-CoV-2 in the population attending vaccination centers in Thailand is considered pivotal. Objective: To investigate the incidence and factors associated with adverse events following the administration of the COVID-19 vaccine in the Ubon Ratchathani province. Methods: We analyzed data from individuals who received COVID-19 vaccinations in Ubon Ratchathani province between June 1, 2021, and July 31, 2022. Results: The study examined data from 2,955,978 COVID-19 vaccines administered in Ubon Ratchathani province. Among these, 3.34% experienced an AEFI, further categorized into events occurring within 30 min (0.17%) and after 30 min (3.19%) of vaccination. The occurrences were higher in females compared to males. The age groups exhibited distinct AEFI rates, with children aged 5–17 years and adults aged 18–60 years facing a higher risk. Additionally, individuals with comorbidities are more likely to experience AEFI. The brand of the vaccine and the number of doses administered also influenced AEFI rates. This comprehensive analysis provides valuable insights into AEFI reports, vaccine brands, and associated risk factors, and offers crucial information for vaccine safety monitoring and management. Conclusion: This COVID-19 vaccine adverse events study revealed that higher odds of adverse events were associated with being female, younger, having comorbidities, brand of vaccines, or getting over two doses. These findings provide valuable real-world safety information regarding different COVID-19 vaccines, aiding healthcare professionals and policymakers in effectively monitoring and managing vaccine-related AEFI.

KEYWORDS

• factors
• adverse events following immunization (AEFI)
• covid-19 vaccine
• Thailand

Showing references and in-text citations exactly as published.

• DOI10.18549/PharmPract.2024.4.3062Copy

RELATED ARTICLES

Matched on section and article type within this issue of PP.

• Article · VOLUME 22, ISSUE 4Assessment of Jordanian Pharmacists' Knowledge and Awareness of Liraglutide Injection and their Practice in Counseling Obesity PatientsJumanah D. Al-Shawabkeh · pp. 1–13Original ResearchSame type: Article
• Article · VOLUME 22, ISSUE 4Evaluating the management of urinary tract infections by community pharmacists in Queensland, AustraliaJean M Spinks, Esther TL Lau, Beverley D Glass, Lisa M Nissen · pp. 1–10Original ResearchSame type: Article
• Article · VOLUME 22, ISSUE 4Association between Toll-Like Receptor 4 Gene and inflammatory bowel disease among Jordanian patientsMalek Zihlif, Zainab Zakaraya, Rawan Nael, Abed Al-Rahman Al-Shudiefat, Mohammad Alshhab, Ahmad Sundookah, Ahmad R. Alsayed · pp. 1–7Original ResearchSame type: Article
• Article · VOLUME 22, ISSUE 4The Role of Clinical Pharmacist in Monitoring Drug Therapy in the Cardiovascular and Coronary Care Units in LibyaAsmaa S.H. Alhomri, Ahmed A. Battah, Ahmed A. Elberry, Eman K.A. Abdelall, Raghda R.S. Hussein · pp. 1–13Original ResearchSame type: Article